Broxyquinoline (Dibromohydroxyquinoline) is a potent severe fever with thrombocytopenia syndrome virus (SFTSV) inhibitor with an IC50 of 5.8 μM. Broxyquinoline is an antiprotozoal agent[1-2].
In Vitro
Four compounds displayed efficacies against parasite growth in vitro with low micromolar IC(50) values. The effective compounds were broxyquinoline (IC(50) 64.9 μM), cloxyquin (IC(50) 25.1 μM), cloxacillin sodium (IC(50) 36.2 μM) and sodium dehydrocholate (IC(50) 53.2 μM).[2]
SMILES
OC1=C2N=CC=CC2=C(Br)C=C1Br
靶点
Parasite
数据来源文献
[1]. Shuofeng Yuan, et al. Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus. Viruses. 2019 Apr 25;11(4):385. [2]. Fritzler JM, et al. Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP). J Antimicrob Chemother. 2012 Mar;67(3):609-17.